GRAMD1C

Summary

GRAMD1C (GRAM domain containing 1C, HGNC:25252) is a protein-coding gene on chromosome 3q13.31, encoding Protein Aster-C (Q8IYS0). Cholesterol transporter that mediates non-vesicular transport of cholesterol from the plasma membrane (PM) to the endoplasmic reticulum (ER).

Predicted to enable cholesterol binding activity and cholesterol transfer activity. Predicted to be involved in cellular response to cholesterol and intracellular sterol transport. Predicted to be located in endoplasmic reticulum; membrane; and organelle membrane contact site. Predicted to be active in endoplasmic reticulum membrane; endoplasmic reticulum-plasma membrane contact site; and plasma membrane.

Source: NCBI Gene 54762 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 99 total
• Druggable target: yes
• MANE Select transcript: NM_017577

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25252
Approved symbol	GRAMD1C
Name	GRAM domain containing 1C
Location	3q13.31
Locus type	gene with protein product
Status	Approved
Aliases	LAMc, DKFZp434C0328
Ensembl gene	ENSG00000178075
Ensembl biotype	protein_coding
OMIM	620180
Entrez	54762

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 10 protein_coding, 4 protein_coding_CDS_not_defined, 4 retained_intron, 2 nonsense_mediated_decay

ENST00000358160, ENST00000440446, ENST00000462838, ENST00000463760, ENST00000466898, ENST00000467895, ENST00000471031, ENST00000472026, ENST00000472384, ENST00000479212, ENST00000484714, ENST00000486457, ENST00000488680, ENST00000491038, ENST00000498183, ENST00000870487, ENST00000870488, ENST00000870489, ENST00000870490, ENST00000870491

RefSeq mRNA: 2 — MANE Select: NM_017577 NM_001172105, NM_017577

CCDS: CCDS33826, CCDS54625

Canonical transcript exons

ENST00000358160 — 18 exons

Exon	Start	End
ENSE00001914796	113838788	113838936
ENSE00003469879	113933511	113933653
ENSE00003476254	113934432	113934535
ENSE00003477240	113915701	113915838
ENSE00003492677	113908958	113909120
ENSE00003517077	113882752	113882832
ENSE00003531006	113904140	113904272
ENSE00003553225	113940240	113940345
ENSE00003566636	113901031	113901146
ENSE00003580544	113938086	113938143
ENSE00003600375	113876165	113876260
ENSE00003604806	113936266	113936442
ENSE00003622316	113844503	113844649
ENSE00003635294	113945398	113947174
ENSE00003636864	113939886	113939996
ENSE00003639510	113875484	113875587
ENSE00003664573	113930714	113930832
ENSE00003688970	113869507	113869591

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 94.99.

FANTOM5 (CAGE): breadth broad, TPM avg 2.8074 / max 108.9174, expressed in 847 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
37978	1.0362	492
37977	0.8084	260
37982	0.5708	141
37976	0.3631	149
37983	0.0213	6
37981	0.0076	3

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	94.99	gold quality
bronchial epithelial cell	CL:0002328	92.78	gold quality
epithelium of nasopharynx	UBERON:0001951	92.32	gold quality
germinal epithelium of ovary	UBERON:0001304	91.79	gold quality
sperm	CL:0000019	91.19	gold quality
epithelium of bronchus	UBERON:0002031	91.05	gold quality
bronchus	UBERON:0002185	90.16	gold quality
right uterine tube	UBERON:0001302	89.80	gold quality
nephron tubule	UBERON:0001231	89.72	gold quality
palpebral conjunctiva	UBERON:0001812	89.53	gold quality
body of pancreas	UBERON:0001150	88.99	gold quality
renal medulla	UBERON:0000362	88.70	gold quality
esophagus squamous epithelium	UBERON:0006920	88.58	gold quality
upper leg skin	UBERON:0004262	88.55	gold quality
male germ cell	CL:0000015	88.49	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.95	gold quality
amniotic fluid	UBERON:0000173	87.12	gold quality
caput epididymis	UBERON:0004358	86.92	gold quality
kidney epithelium	UBERON:0004819	86.44	gold quality
right lobe of liver	UBERON:0001114	86.30	gold quality
kidney	UBERON:0002113	85.69	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.48	gold quality
endometrium	UBERON:0001295	85.18	gold quality
pigmented layer of retina	UBERON:0001782	85.02	gold quality
adult mammalian kidney	UBERON:0000082	84.91	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.84	gold quality
endothelial cell	CL:0000115	84.71	silver quality
pancreas	UBERON:0001264	84.69	gold quality
cortex of kidney	UBERON:0001225	84.62	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	84.46	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	19.82
E-ANND-3	yes	6.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

92 targeting GRAMD1C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-3671	99.90	73.04	3897

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	gramd1c	ENSDARG00000076238
mus_musculus	Gramd1c	ENSMUSG00000036292
rattus_norvegicus	Gramd1c	ENSRNOG00000053406
drosophila_melanogaster	GramD1B	FBGN0085423
caenorhabditis_elegans	ZC328.3	WBGENE00022593

Paralogs (4): GRAMD1B (ENSG00000023171), GRAMD1A (ENSG00000089351), GRAMD2B (ENSG00000155324), GRAMD2A (ENSG00000175318)

Protein

Protein identifiers

Protein Aster-C — Q8IYS0 (reviewed: Q8IYS0)

Alternative names: GRAM domain-containing protein 1C

All UniProt accessions (6): Q8IYS0, B4DF12, C9J7B8, C9K0V2, E9PHT3, F8WCA8

UniProt curated annotations — full annotation on UniProt →

Function. Cholesterol transporter that mediates non-vesicular transport of cholesterol from the plasma membrane (PM) to the endoplasmic reticulum (ER). Contains unique domains for binding cholesterol and the PM, thereby serving as a molecular bridge for the transfer of cholesterol from the PM to the ER. Plays a crucial role in cholesterol homeostasis and has the unique ability to localize to the PM based on the level of membrane cholesterol. In lipid-poor conditions localizes to the ER membrane and in response to excess cholesterol in the PM is recruited to the endoplasmic reticulum-plasma membrane contact sites (EPCS) which is mediated by the GRAM domain. At the EPCS, the sterol-binding VASt/ASTER domain binds to the cholesterol in the PM and facilitates its transfer from the PM to ER.

Subcellular location. Endoplasmic reticulum membrane. Cell membrane.

Domain organisation. GRAM domain binds phosphatidylserine in the PM and mediates protein recruitment to endoplasmic reticulum-plasma membrane contact sites (EPCS) in response to excess cholesterol in the PM. VASt (VAD1 Analog of StAR-related lipid transfer) domain, also known as ASTER (Greek for star) domain is a sterol-binding domain.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IYS0-1	1	yes
Q8IYS0-2	2

RefSeq proteins (2): NP_001165576, NP_060047* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004182	GRAM	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR031968	VASt	Domain
IPR051482	Cholesterol_transport	Family

Pfam: PF02893, PF16016

UniProt features (24 total): strand 7, helix 3, turn 3, region of interest 3, domain 2, chain 1, transmembrane region 1, sequence conflict 1, compositionally biased region 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6GN5	X-RAY DIFFRACTION	1.41

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IYS0-F1	68.39	0.30

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 136 (showing top): LEE_NEURAL_CREST_STEM_CELL_DN, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, GGGCATT_MIR365, GOBP_RESPONSE_TO_STEROL, OCT1_03, CAIRO_HEPATOBLASTOMA_DN, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, GOBP_CELLULAR_RESPONSE_TO_CHOLESTEROL, GOZGIT_ESR1_TARGETS_UP, GOBP_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_STEROL, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN

GO Biological Process (3): intracellular sterol transport (GO:0032366), cellular response to cholesterol (GO:0071397), lipid transport (GO:0006869)

GO Molecular Function (4): cholesterol binding (GO:0015485), cholesterol transfer activity (GO:0120020), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (7): endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), endoplasmic reticulum-plasma membrane contact site (GO:0140268), endoplasmic reticulum (GO:0005783), membrane (GO:0016020), organelle (GO:0043226), organelle membrane contact site (GO:0044232)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
binding	2
intracellular anatomical structure	1
sterol transport	1
intracellular lipid transport	1
cellular response to sterol	1
response to cholesterol	1
cellular response to alcohol	1
transport	1
lipid localization	1
sterol binding	1
alcohol binding	1
cholesterol binding	1
sterol transfer activity	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
organelle membrane contact site	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle	1

Protein interactions and networks

STRING

492 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GRAMD1C	GTPBP8	Q8N3Z3	559
GRAMD1C	LHFPL7	Q6ICI0	500
GRAMD1C	SPICE1	Q8N0Z3	487
GRAMD1C	TMEM205	Q6UW68	464
GRAMD1C	ANTXRL	A6NF34	460
GRAMD1C	TTC9	Q92623	458
GRAMD1C	WDR17	Q8IZU2	454
GRAMD1C	MSLNL	Q96KJ4	448
GRAMD1C	SVOPL	Q8N434	440
GRAMD1C	EFR3B	Q9Y2G0	421
GRAMD1C	TM9SF3	Q9HD45	416
GRAMD1C	GCNT7	Q6ZNI0	412
GRAMD1C	PCDHB1	Q9Y5F3	401
GRAMD1C	KICS2	Q96MD2	393
GRAMD1C	NAA50	Q9GZZ1	392

IntAct

34 interactions, top by confidence:

A	B	Type	Score
CD151	GRAMD1C	psi-mi:“MI:0915”(physical association)	0.850
GRAMD1C	CD151	psi-mi:“MI:0915”(physical association)	0.850
FIBP	CDK5	psi-mi:“MI:0914”(association)	0.840
CD72	GRAMD1C	psi-mi:“MI:0915”(physical association)	0.560
EVA1C	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
TMX1	NRP1	psi-mi:“MI:0914”(association)	0.530
HEATR3	SLC27A2	psi-mi:“MI:0914”(association)	0.530
GRAMD2B	EFCAB14	psi-mi:“MI:0914”(association)	0.530
PARP2	GRAMD1C	psi-mi:“MI:0557”(adp ribosylation reaction)	0.440
CSNK2A1	RPS3A	psi-mi:“MI:0914”(association)	0.350
CSNK2A2	VWA8	psi-mi:“MI:0914”(association)	0.350
TTYH1	TMEM223	psi-mi:“MI:0914”(association)	0.350
CLRN2	FAM234B	psi-mi:“MI:0914”(association)	0.350
SCARA3	DEGS1	psi-mi:“MI:0914”(association)	0.350
GRAMD1B	ADD2	psi-mi:“MI:0914”(association)	0.350
SLC16A2	QNG1	psi-mi:“MI:0914”(association)	0.350
GRAMD1B	TRAPPC10	psi-mi:“MI:0914”(association)	0.350
CALM1	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
FIBP	AGRN	psi-mi:“MI:0914”(association)	0.350
SLC16A2	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
FHIP2B	VWA8	psi-mi:“MI:2364”(proximity)	0.270
CD72	GRAMD1C	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (41): GRAMD1C (Two-hybrid), GRAMD1C (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), GRAMD1C (Reconstituted Complex), GRAMD1C (Two-hybrid), GRAMD1C (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), GRAMD1C (Proximity Label-MS), GRAMD1C (Two-hybrid)

ESM2 similar proteins: A9SV60, A9SY64, B9FFA3, B9FS33, C0SUW7, C6KIE6, F4HP88, F4I7L1, F4IHJ0, F4J7S8, F4JLE5, F4JTI1, F4JVA6, F4JVA9, F4JYJ3, F4K6D3, I1HNB2, K7TQE3, O22977, O60502, Q0D5P3, Q501H5, Q5RC33, Q5W6L9, Q6AUQ7, Q8CI52, Q8GXC6, Q8IYS0, Q8LPQ7, Q8RXT5, Q8VIJ5, Q93ZE9, Q94A09, Q94A34, Q94B77, Q9C5S2, Q9C9U5, Q9EQQ9, Q9FKG6, Q9FKV5

Diamond homologs: A1CFB3, A1CYS1, A2QNQ5, A7A179, A7ERM5, A7KAK6, A7KAN4, A7TF84, C4B4E5, I1S8Q3, P0CN90, P0CN91, P64866, P9WN06, P9WN07, Q06321, Q0CKU4, Q0UY53, Q2U0C3, Q4WID6, Q54IL5, Q5A950, Q5B4C9, Q5RC33, Q6BN88, Q6C8M8, Q6CUV2, Q751Z4, Q7S1I0, Q8C115, Q8CI52, Q8IVE3, Q8IYS0, Q8N4B1, Q8NJS1, Q9M8Z7, Q9XIG1, Q9Y751, Q00IB7, Q08001

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	76
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3512 predictions. Top by Δscore:

Variant	Effect	Δscore
3:113844497:TTCCA:T	acceptor_loss	1.0000
3:113844498:TCCAG:T	acceptor_loss	1.0000
3:113844499:CCAG:C	acceptor_loss	1.0000
3:113844500:CAG:C	acceptor_loss	1.0000
3:113844501:AGGTG:A	acceptor_loss	1.0000
3:113844502:G:GC	acceptor_loss	1.0000
3:113844578:G:GT	donor_gain	1.0000
3:113875588:G:GG	donor_gain	1.0000
3:113904270:G:GT	donor_gain	1.0000
3:113904270:GGA:G	donor_gain	1.0000
3:113904271:GA:G	donor_gain	1.0000
3:113904271:GAG:G	donor_gain	1.0000
3:113904273:GTTA:G	donor_gain	1.0000
3:113904274:T:G	donor_gain	1.0000
3:113909121:G:T	donor_loss	1.0000
3:113909122:T:A	donor_loss	1.0000
3:113930535:A:T	donor_gain	1.0000
3:113930705:T:TA	acceptor_gain	1.0000
3:113930708:T:A	acceptor_gain	1.0000
3:113930712:A:AG	acceptor_gain	1.0000
3:113930713:G:GA	acceptor_gain	1.0000
3:113930713:GAT:G	acceptor_gain	1.0000
3:113930713:GATGT:G	acceptor_gain	1.0000
3:113930829:GCAG:G	donor_gain	1.0000
3:113930833:G:GA	donor_loss	1.0000
3:113930834:T:A	donor_loss	1.0000
3:113933509:A:AG	acceptor_gain	1.0000
3:113933510:G:GG	acceptor_gain	1.0000
3:113933648:GC:G	donor_gain	1.0000
3:113933885:G:GT	donor_gain	1.0000

AlphaMissense

4346 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:113875522:G:A	G100R	1.000
3:113875522:G:C	G100R	1.000
3:113876231:G:C	A144P	1.000
3:113875494:T:G	C90W	0.999
3:113875496:C:A	A91D	0.999
3:113875499:T:C	L92P	0.999
3:113875514:T:C	L97S	0.999
3:113875523:G:A	G100E	0.999
3:113875523:G:T	G100V	0.999
3:113875526:G:C	R101P	0.999
3:113875529:T:C	L102P	0.999
3:113875555:T:C	F111L	0.999
3:113875556:T:C	F111S	0.999
3:113875557:C:A	F111L	0.999
3:113875557:C:G	F111L	0.999
3:113876214:C:A	A138D	0.999
3:113876223:T:C	I141T	0.999
3:113876232:C:A	A144D	0.999
3:113882759:T:C	F156S	0.999
3:113882777:G:T	R162M	0.999
3:113869555:T:C	F75L	0.998
3:113869557:C:A	F75L	0.998
3:113869557:C:G	F75L	0.998
3:113875492:T:C	C90R	0.998
3:113875493:G:A	C90Y	0.998
3:113875535:T:C	L104P	0.998
3:113875550:T:C	L109P	0.998
3:113875554:T:G	C110W	0.998
3:113876203:G:C	K134N	0.998
3:113876203:G:T	K134N	0.998

dbSNP variants (sampled 300 via entrez): RS1000034899 (3:113882098 G>A), RS1000039589 (3:113905290 A>G), RS1000040390 (3:113843379 T>C), RS1000061758 (3:113826940 T>A), RS1000107412 (3:113837327 G>A), RS1000109283 (3:113905784 C>T), RS1000120285 (3:113851023 T>C), RS1000141162 (3:113897071 C>G), RS1000247659 (3:113831185 A>G), RS1000281264 (3:113944986 A>G), RS1000289126 (3:113850618 T>G), RS1000323237 (3:113890249 A>G), RS1000380397 (3:113837684 C>T), RS1000406270 (3:113868262 G>C), RS1000433257 (3:113905648 TATA>T)

Disease associations

OMIM: gene MIM:620180 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006585_135	Blood protein levels	4.000000e-133
GCST009218_47	Lateral ventricle temporal horn volume	3.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067584 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation, increases expression	6
methylmercuric chloride	decreases expression	3
sodium arsenite	increases expression, affects cotreatment, decreases expression, increases abundance	3
trichostatin A	affects expression, decreases expression, increases expression	2
mercuric bromide	decreases expression, affects cotreatment	2
Acetaminophen	decreases expression	2
Estradiol	decreases expression, affects cotreatment	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tretinoin	increases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
GSK-J4	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
butyraldehyde	increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
nickel sulfate	increases expression	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
clothianidin	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1
(+)-JQ1 compound	decreases expression	1
Vorinostat	increases expression	1
Air Pollutants	decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5550807	Binding	Binding affinity to aster C (unknown origin)	Fluorescent probes and degraders of the sterol transport protein Aster-A. — Bioorg Med Chem

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists